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Abstract A novel myosin light chain kinase (MLCK) cDNA
was isolated from a HeLa cell cDNA library. The deduced amino
acid sequence was identical to that of a zipper-interacting protein
kinase (ZIPK) which mediates apoptosis [Kawai et al. (1998)
Mol. Cell. Biol. 18, 1642^1651]. Here we found that HeLa ZIPK
phosphorylated the regulatory light chain of myosin II (MRLC)
at both serine 19 and threonine 18 in a Ca2+/calmodulin
independent manner. Phosphorylation of myosin II by HeLa
ZIPK resulted in activation of actin-activated MgATPase
activity of myosin II. HeLa ZIPK is the first non-muscle
MLCK that phosphorylates MRLC at two sites.
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1. Introduction
In most eukaryotic cells, it is considered that myosin II
plays an important role during cytokinesis [1^3]. However,
the molecular mechanisms for controlling of myosin II still
remain unknown. Phosphorylation of the regulatory light
chain of myosin II (MRLC) regulates positively and nega-
tively both smooth muscle and non-muscle myosin. The ac-
tin-activated MgATPase activity of myosin II is increased by
phosphorylation of MRLC by Ca2/calmodulin-dependent
myosin light chain kinase (MLCK) [4]. The phosphorylation
sites of MRLC by smooth muscle (sm) MLCK are mainly
serine 19 and, under some conditions, threonine 18 and serine
19. This phosphorylation also promotes assembly of myosin
¢lament, at least in vitro [5]. MRLC was also phosphorylated
by protein kinase C (PKC) at serine 1 and/or serine 2 and
threonine 9 [6,8]. Phosphorylation by PKC inhibits the in-
crease in MgATPase activity of myosin II phosphorylated
by smMLCK [7,8].
Recent evidence showed that phosphorylated MRLC at
serine 19 localized in the contractile ring of dividing mamma-
lian cells, suggesting that phosphorylation of MRLC plays an
important role during cytokinesis [9,10]. Consequently, we
tried to investigate the kinase(s) which phosphorylate
MRLC during cytokinesis. In order to search for such kin-
ase(s), we screened a HeLa cell cDNA library with the frag-
ment of the bovine stomach MLCK gene including kinase and
calmodulin regulatory domains as a probe. We ¢rst found
that one serine/threonine kinase, HeLa zipper-interacting pro-
tein kinase (ZIPK), from non-muscle cells phosphorylated
MRLC at both serine 19 and threonine 18. Furthermore,
phosphorylation of intact myosin II by HeLa ZIPK enhanced
the actin-activated MgATPase activity of myosin II. HeLa
ZIPK is a candidate for phosphorylation of MRLC at both
serine 19 and threonine 18 in non-muscle cells.
2. Materials and methods
2.1. Materials and chemicals
Myosin II and smMLCK were puri¢ed from chicken gizzard
[11,12]. Light chains from myosin II (MLCs) were obtained as de-
scribed [13]. Actin was prepared from rabbit skeletal muscle by the
method of Spudich and Watt [14]. G-actin was further puri¢ed by gel
¢ltration. Calmodulin from bovine brain was purchased from Sigma.
Other materials and chemicals were obtained from commercial sour-
ces.
2.2. Cell culture
HeLa cells (RCB007; just like ATCC CCL2, HeLa) were obtained
from the Riken Cell Bank (Tsukuba, Japan) and were grown as de-
scribed previously [15].
2.3. Construction of HeLa cell cDNA library
The HeLa cell cDNA library was constructed using lambda ZAPII
as a vector. Messenger RNA was extracted from exponentially grow-
ing cells using a messenger RNA isolation kit (Stratagene). The
cDNA synthesis was performed using a ZAP cDNA library synthesis
kit (Stratagene). The ¢rst strand was synthesized by priming an oli-
go(dT) linker-primer carrying a XhoI adapter. After the second strand
was synthesized, the cDNA termini were blunted by Klenow frag-
ments and ligated with EcoRI adapters. XhoI digestion was performed
to generate a XhoI site at the 5P end. The synthesized cDNAs were
ligated into XhoI-EcoRI sites of the lambda ZAPII vector.
Packaging of lambda DNA in vitro was performed with GIGA
PACK II Gold (Stratagene) according to the manufacturer’s instruc-
tions.
2.4. Screening of HeLa cell cDNA library
The bovine stomach MLCK cDNA clone (pSL17), kindly provided
by Dr. H. Kobayashi [16], was digested with SalI and HindIII. The
obtained 1.0 kb fragment was used as a probe. Screening of the HeLa
cell cDNA library in lambda ZAPII was performed using the ECL
direct nucleic acid labeling and detection system (Amersham Pharma-
cia Biotech). Recombinant phages of 4U105 pfu were plated with
Escherichia coli XL1 Blue and blotted onto Hybond N membranes
(Amersham Pharmacia Biotech). The cDNA fragments prepared
above were labeled with horseradish peroxidase (HRP) and used as
probes. Hybridization using 10 ng/ml of HRP-labeled probes in the
recommended hybridization bu¡er and washing and detection proce-
dures was performed according to the manufacturer’s instructions.
The membranes were used to expose to X-ray ¢lm.
2.5. Determination of complete cDNA sequences
The cDNA inserts were subcloned into pBluescript SK3 from the
ZAPII vector in vivo using an ExAssist/SOLR system (Toyobo). A
series of deletion mutants of subclones were prepared for sequencing
using exonuclease III. Sequencing was done with the Model 373S
DNA sequencing system (Perkin-Elmer) and ALFexpress II (Amer-
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sham Pharmacia Biotech). Sequences were assembled with the soft-
ware DNASIS (Hitachi Software Engineering).
2.6. Plasmid construction and expression of recombinant kinase
The cDNA clones encoding the complete amino acids of HeLa
ZIPK were in-frame inserted into vector pGEX-5X-3 (Amersham
Pharmacia Biotech) in order to express the glutathione S-transferase
(GST) fusion protein. E. coli cells were cultured in 2UYT medium
containing 10 mg/ml Bacto yeast extract (Difco), 16 mg/ml Bacto
tryptone (Difco), 5 mg/ml NaCl and 100 Wg/ml ampicillin at 37‡C
with vigorous agitation. After 2.5 h culture, protein expression was
induced by adding isopropyl-L-D-thiogalactopyranoside to a ¢nal con-
centration of 1 mM. After an additional 2 h at 37‡C, cells were
harvested and lysed by sonication in cold phosphate-bu¡ered saline
containing 1 mM phenylmethylsulfonyl £uoride (PMSF), 10 mg/ml
leupeptin, and 1 mM dithiothreitol (DTT), and GST-HeLa ZIPK
fusion protein was puri¢ed with a glutathione-Sepharose 4B (Amer-
sham Pharmacia Biotech) as described by the manufacturer.
2.7. Protein kinase assay
Phosphorylation of isolated MLCs by GST-HeLa ZIPK was car-
ried out in a reaction mixture (27 mM Tris-HCl (pH 8.0), 1 mM
EGTA, 8 mM MgCl2, 10 mM NaCl, 0.01 mM DTT, 0.1 mM
PMSF, 0.3 Wg/ml leupeptin, 0.3 Wg/ml pepstatin A, 0.5 WM calyculin
A and 0.18 mM [Q-32P]ATP) containing 0.11 mg/ml MLCs, 1.25 Wg/ml
GST-HeLa ZIPK and variable amounts of CaCl2 to give the required
pCa values with or without 50 Wg/ml calmodulin (CaM). Phospho-
rylation of intact myosin II by GST-HeLa ZIPK was carried out in a
reaction mixture (28.5 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1.5 mM
MgCl2, 50 mM KCl, 40 WM PMSF, 0.5 WM calyculin A, 0.5 mM
L-mercaptoethanol and 0.18 mM [Q-32P]ATP) containing 3.5 mg/ml
myosin II and 1.25 Wg/ml GST-HeLa ZIPK. Both reaction mixtures
for the isolated MLCs and myosin II were incubated for 30 min at
25‡C and subjected to SDS-PAGE. The radiolabeled bands were
visualized by the Bio Imaging Analyzer BAS 2000 (Fuji).
2.8. Two-dimensional phosphopeptide mapping analysis
Phosphorylation of isolated MLCs by GST-HeLa ZIPK was car-
ried out in the same reaction mixture as described above containing
0.11 mg/ml MLCs and 125 Wg/ml GST-HeLa ZIPK for 6 min at 25‡C.
Phosphorylation of MLCs by smMLCK was done in a bu¡er (20 mM
Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM EGTA, 2 mM CaCl2,
3.8 mM MgCl2, 20 Wg/ml CaM, 0.3 mM DTT, 1 mM PMSF,
1.4 Wg/ml leupeptin, 1.4 Wg/ml pepstatin A and 1 mM [Q-32P]ATP)
containing 0.5 mg/ml MLCs and 0.1 mg/ml smMLCK for 30 min at
25‡C. 32P-labeled MRLC was separated by SDS-PAGE, and excised
from the gel. Two-dimensional phosphopeptide mapping was done as
described previously [17] except for using a cellulose plate (TLC pre-
coated plates (glass) cellulose: Merck) instead of a silica gel plate
(Merck).
2.9. Assay of MgATPase activity
The MgATPase activity of myosin II unphosphorylated or phos-
phorylated by GST-HeLa ZIPK was assayed in a reaction mixture
containing 40 mM Tris-HCl (pH 7.4), 15 mM KCl, 2 mM MgCl2, 1.5
mM EGTA, 1.2 WM reduced glutathione, 1.5 mM ATP, 10 WM
PMSF, 0.2 mM L-mercaptoethanol, 0.2 mg/ml of F-actin and 0.24
mg/ml of myosin II with or without 50 Wg/ml GST-HeLa ZIPK for
20 min at 25‡C. Phosphorylation of myosin II was carried out by
incubating 0.8 mg/ml of myosin II with 0.16 mg/ml GST-HeLa
ZIPK in a bu¡er containing 40 mM Tris-HCl (pH 7.5), 10 mM
KCl, 1.5 mM MgCl2, 1 mM EGTA, 0.04 mM PMSF, 0.6 mM L-
mercaptoethanol and 2 mM ATP for 1 h at 25‡C. The actin-activated
MgATPase reaction was started by addition of F-actin to the reaction
mixture. Inorganic phosphate was determined by using a IATRON
PiSET (IATRoN Lab.) according to the method of Fiske and Sub-
barow [18].
2.10. Other procedures
SDS-PAGE was carried out by the method of Blattler et al. [19]
with 15% polyacrylamide slab gels, except that the bu¡er system of
Laemmli [20] was used.
3. Results and discussion
In order to search for the kinase(s) that phosphorylate
MRLC, we screened a HeLa cell cDNA library under low
stringency conditions with a HRP-labeled partial cDNA frag-
ment of the bovine stomach MLCK cDNA. This fragment
was obtained by digestion with the restriction enzymes SalI
and HindIII and encoded the kinase and the calmodulin reg-
ulatory domains of smMLCK [16]. After screening 4U105
recombinant phages with this fragment as a probe, several
clones encoding kinases were obtained. One of them was char-
acterized by determination of the nucleotide sequence. The
decided nucleotide sequence was 2079 bp and the deduced
amino acid sequence was identical to that of ZIPK from hu-
man placenta in the protein sequence database [21]. ZIPK was
¢rst identi¢ed as a kinase which is a mediator of apoptosis
[21]. However, the nucleotide sequence of our clone was
slightly di¡erent from that of placenta ZIPK in both coding
and untranslated regions (data not shown). The kinase do-
main of HeLa ZIPK had 48% amino acid sequence identity
to that of smMLCK [16] (Fig. 1). Furthermore, it is also 81%
identical to the kinase domain of death-associated protein
Fig. 1. Comparison of the kinase domain of HeLa ZIPK, HeLa DAPK and smMLCK. Identical amino acids are boxed. The nucleotide se-
quence data of HeLa ZIPK will appear in the DDBJ/EMBL/GenBank nucleotide sequence databases with the accession number AB022341.
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kinase (DAPK) from HeLa cells which plays an important
role in Q-interferon-induced cell death [22]. Because both
DAPK [23] and smMLCK phosphorylate MRLC, we inves-
tigated the ability of HeLa ZIPK to phosphorylate isolated
MRLC or MRLC of intact myosin II (Fig. 2A). The cDNA
encoded by HeLa ZIPK was expressed as GST fusion protein
in E. coli. A⁄nity puri¢ed GST-HeLa ZIPK phosphorylated
both MRLC of intact myosin II and isolated MRLC in the
absence of Ca2/CaM (Fig. 2A). It is well known that both
DAPK and smMLCK phosphorylate MRLC in a Ca2/CaM-
dependent manner. Therefore, to know whether the activity of
HeLa ZIPK is regulated by Ca2/CaM, various concentra-
tions of CaCl2 to give required values of pCa were added to
the reaction mixture in the absence or presence of CaM (Fig.
2B). However, any concentrations of Ca2 or Ca2/CaM did
not in£uence the activity of GST-HeLa ZIPK (Fig. 2B). Fur-
thermore, HeLa ZIPK lacked the CaM regulatory domain of
DAPK or smMLCK as well as placenta ZIPK [21]. These
data suggest that HeLa ZIPK phosphorylates MRLC in a
Ca2/CaM-independent manner.
MRLC was phosphorylated ¢rst at serine 19 and second at
threonine 18 by smMLCK [24]. To determine the phospho-
rylation sites of MRLC by HeLa ZIPK, two-dimensional
phosphopeptide mapping of phosphorylated MRLC by either
GST-HeLa ZIPK or smMLCK was performed (Fig. 3). In
this condition, smMLCK phosphorylates MRLC at both ser-
ine 19 and threonine 18. The pattern of the mapping of phos-
phorylated MRLC by GST-HeLa ZIPK was identical to that
by smMLCK. When GST-HeLa ZIPK phosphorylated
MRLC at a low concentration (1.25 Wg/ml), phosphorylation
of MRLC still occurred at both residues. A phosphoamino
acid analysis revealed that phosphorylation of MRLC by
GST-HeLa ZIPK was at both serine and threonine residues.
These results suggest that HeLa ZIPK phosphorylated MRLC
¢rst at serine 19 and second at threonine 18. Phosphorylation
of MRLC at serine 19 and threonine 18 by smMLCK in-
creased the actin-activated MgATPase activity of smooth
muscle and non-muscle myosin [25,26]. Fig. 4 showed that
phosphorylation of myosin II by GST-HeLa ZIPK also in-
creased the actin-activated MgATPase activity.
In this paper, we showed that the serine/threonine kinase,
HeLa ZIPK, phosphorylated MRLC at both serine 19 and
threonine 18 as smooth muscle smMLCK did. Its activity
for phosphorylation of MRLC was not regulated by Ca2/
CaM. Furthermore, the phosphorylation of MRLC of intact
Fig. 2. Phosphorylation of MLCs of intact myosin II and isolated
MLCs by HeLa ZIPK. A: MLCs of intact myosin II and isolated
MLCs were phosphorylated by GST-HeLa ZIPK. GST-HeLa ZIPK
phosphorylated both MRLC of intact myosin II and isolated
MRLC in the absence of Ca2/CaM (arrows). Only GST did not
phosphorylate MRLC in the same condition (data not shown).
B: Ca2 sensitivity of HeLa ZIPK activity. Isolated MLCs were
phosphorylated by GST-HeLa ZIPK at various values of pCa in
the absence (left panel) and presence (right panel) of calmodulin.
Fig. 3. Identi¢cation of the phosphorylation site of MRLC by
HeLa ZIPK. MRLC was phosphorylated by GST-HeLa ZIPK or
smMLCK. Phosphorylated MRLC was digested with trypsin and
processed on a cellulose plate for electrophoresis (horizontal) fol-
lowed by chromatography (vertical). Open circles denote origins.
Fig. 4. E¡ect of phosphorylation of myosin II by HeLa ZIPK on
the actin-activated MgATPase activity. Myosin II was incubated
with (+) or without (3) GST-HeLa ZIPK.
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myosin II enhanced the MgATPase activity. These data sug-
gest that HeLa ZIPK phosphorylates MRLC of myosin II
and increases its MgATPase activity in a Ca2/CaM-inde-
pendent manner. Recently, it has been reported that two kinds
of serine/threonine kinases phosphorylate MRLC predomi-
nantly at serine 19 in non-muscle cells. Phosphorylation of
myosin II by these non-muscle (nm) MLCKs resulted in en-
hancement of the MgATPase activity of myosin II in vitro.
One is mitogen-activated protein kinase-activated protein kin-
ase-4 from sea urchin eggs [26] and another is Rho-kinase
from bovine brain [27]. In contrast with these, nmMLCKs
which phosphorylate MRLC at both serine 19 and threonine
18 from non-muscle cells have never been reported previously.
Therefore, HeLa ZIPK is the ¢rst nmMLCK which can phos-
phorylate MRLC at two sites.
Recently, Ko«gel et al. reported that a DAPK homologue,
Dlk, phosphorylates core histones H3 and H4 [28]. Whether
MRLC and/or histones represent physiological substrates re-
mains to be elucidated. However, it is attractive to speculate
that these kinases are involved in regulation of nuclear func-
tions through cytoskeletal structures including myosins. We
are now investigating the localization of phosphorylated
MRLC at both serine 19 and threonine 18 in HeLa cells. In
future, it is necessary to investigate whether HeLa ZIPK con-
tributes to phosphorylation of MRLC at two sites in cytoki-
nesis of non-muscle cells.
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